ReiThera, a CDMO, has appointed Stefano Colloca as its Chief Executive Officer. Stefano brings decades of experience as a leader in viral vector technologies, having co-founded and directed numerous viral vector programs at Okairos Srl, before co-founding ReThera.
Novel HIV vaccine candidate based on Gorilla adenoviral vector (GRAd-HIV) funded by the Bill & Melinda Gates Foundation to alleviate the disease burden and improve the lives of the millions who...
ReiThera announced on Nov. 3, 2022 that it has received operational authorization from the Italian Medicines Agency (AIFA) to open the new production area at its new facility at the Castel Romano Technopole. The 1500-m2 facility will focus on the large-scale production of viral vectors for vaccines and gene therapy.
ROME, Nov. 3, 2022 /PRNewswire/ -- ReiThera, a biotech company dedicated to the development of new technologies, GMP production and the clinical translation of genetic vaccines and products for advanced therapies, today announces that it has received operational authorization from the Italian Medicines Agency (AIFA) to open the new production area at its pharmaceutical facility at the Castel Romano Technopole, for the large-scale production of viral vectors for vaccines and gene therapy.
The CDMO arm of the Terumo Corporation is looking to branch out of Japan and offer its services in other nations.
ReiThera Srl, a biotech company dedicated to the technology development, GMP manufacturing and clinical translation of genetic vaccines and medicinal products for advanced therapies, and Exothera, a full-service contract development and manufacturing organization (CDMO), have entered into a collaboration agreement to develop a large-scale, low cost per dose manufacturing process for the production of ReiThera’s novel vaccines.
ReiThera, a biotech company, announces the preliminary safety and immunogenicity data from the phase 2 clinical COVITAR trial with GRAd-COV2, its novel Covid-19 vaccine candidate.
ReiThera, a biotech company, announces the preliminary safety and immunogenicity data from the phase 2 clinical COVITAR trial with GRAd-COV2, its novel Covid-19 vaccine candidate.
ReiThera, a biotech company, announces the preliminary safety and immunogenicity data from the phase 2 clinical COVITAR trial with GRAd-COV2, its novel Covid-19 vaccine candidate.